The role of the Androgen Receptor (AR) in endometrial cancer aggressiveness: Correlation with other prognostic markers and therapeutic implications. A retrospective observational study
Open Access
- 2 April 2025
- journal article
- Published by Elsevier in Pathology - Research and Practice
- Vol. 269, 155922
Abstract
No abstract availableKeywords
Funding Information
- Fondazione Umberto Veronesi
- Fondazione AIRC per la ricerca sul cancro ETS
- Associazione Italiana per la Ricerca sul Cancro
- Università degli Studi di Genova (PRIN-MIUR 2022)
This publication has 20 references indexed in Scilit:
- Androgen-responsive FOXP4 is a target for endometrial carcinomaCommunications Biology, 2024
- p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trialLaboratory Investigation, 2022
- Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2022
- p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsiesThe Journal of Pathology, 2019
- Androgen receptors are acquired by healthy postmenopausal endometrial epithelium and their subsequent loss in endometrial cancer is associated with poor survivalBritish Journal of Cancer, 2016
- The expression ratios of estrogen receptor α (ERα) to estrogen receptor β1 (ERβ1) and ERα to ERβ2 identify poor clinical outcome in endometrioid endometrial cancerHuman Pathology, 2013
- Integrated genomic characterization of endometrial carcinomaNature, 2013
- Does high-grade endometrioid carcinoma (grade 3 FIGO) belong to type I or type II endometrial cancer? A clinical–pathological and immunohistochemical studyVirchows Archiv, 2010
- Diabetes mellitus and risk of endometrial cancer: a meta-analysisDiabetologia, 2007
- Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classificationVirchows Archiv, 2004